Lowered Affinity Antibodies for Specific Binding Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current control antibodies used in research and therapeutic applications often suffer from poorly defined variable domains, uncertain antigen specificities, and issues like cross-reactivity, making it difficult to distinguish between specific antigen-antibody interactions and nonspecific effects, which complicates the interpretation of biochemical and biological effects.
Innovation Solution
A method for producing recombinant antibodies with reduced binding affinity by identifying amino acids in the complementarity determining regions (CDRs) capable of interaction with antigens and replacing them with non-interacting amino acids without altering the overall antibody structure, resulting in a dissociation constant (KD) of greater than or equal to 10^-7 M, thereby reducing or eliminating binding interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If control antibodies with high binding affinity are used, then specific antigen-antibody interactions are enhanced, but cross-reactivity and nonspecific binding increase making it difficult to distinguish specific effects from nonspecific effects
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions specifically in the CDR regions of the antibody, while leaving the rest of the antibody structure intact. This allows the antibody to maintain its overall structure and Fc region functions while locally modifying the antigen-binding site to reduce affinity and eliminate cross-reactivity.
Solution Approach 2:
The patent changes the binding affinity parameter by substituting amino acids in the CDR regions with amino acids having different chemical properties (e.g., replacing aromatic amino acids like tyrosine or tryptophan with aliphatic amino acids like alanine or valine). This parameter change reduces the binding strength while maintaining the antibody's structural integrity.
2Object-affected harmful factors
If amino acid substitutions are made in CDR regions to reduce binding affinity, then cross-reactivity is minimized, but the ability to bind target antigen is reduced
Solution Approach 1:
The patent applies partial action by making a limited number of amino acid substitutions (typically 1-3 substitutions) in the CDR regions rather than completely eliminating binding capability. This partial modification is sufficient to reduce cross-reactivity while preserving enough binding affinity for the target antigen to maintain experimental utility.
Solution Approach 2:
The patent creates modified antibody variants that copy the overall structure and framework of the parent antibody but with altered CDR sequences. These copied structures maintain the essential antibody architecture while the sequence variations eliminate cross-reactivity.
3Object-affected harmful factors
If multiple amino acid substitutions are made in CDR regions, then binding affinity is reduced more effectively, but the complexity of antibody design and production increases
Solution Approach 1:
The patent segments the antibody molecule by focusing modifications only on the CDR regions (specifically CDR1, CDR2, and CDR3) while leaving the framework regions and Fc portions unchanged. This segmentation allows for systematic design of multiple substitutions without overwhelming complexity, as each CDR can be independently modified.
Solution Approach 2:
The patent creates simplified antibody variants that can be produced through straightforward site-directed mutagenesis techniques. These modified antibodies are designed to be relatively simple to produce and characterize, making them practical tools for control experiments despite the multiple amino acid changes required.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides methods for making novel, rationally designed lowered affinity antibodies. The methods of the present invention make antibodies that have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall (3) dimensional antibody structure. Using the antibodies made using methods of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.